top of page
Search

Prevent, prioritise, diagnose: EVI marks World AMR Awareness Week 2026

Writer: EVI
EVI
1 day ago
2 min read


Every infection prevented is one that doesn’t need antibiotics. This World AMR Awareness Week, EVI highlights three projects that put prevention, prioritisation and rapid diagnosis at the centre of the fight against AMR.

18–24 November 2026


World AMR Awareness Week (WAAW) runs annually from 18 to 24 November to promote coordinated action across the One Health spectrum. This year’s theme, “One Health, One Action: Prevent AMR Now”, recognises that the health of people, animals, plants and the environment is closely connected, and that actions in one sector can affect the others.


The urgency is clear. Bacterial AMR is already associated with more than 4.7 million deaths annually. The updated Global Action Plan on AMR 2026-2036 calls on all countries and sectors to work together under a One Health approach. The burden falls disproportionately on low- and middle-income countries.


Vaccines are one of the most effective tools for prevention. By stopping infections before they occur, they reduce the need for antibiotics and slow the emergence and spread of resistant pathogens. Three EVI-coordinated projects show what this looks like in practice:


Prevent:

  • ShigaPlexIM: Shigella is a WHO priority pathogen for vaccine development, and the leading bacterial cause of diarrhoea. No licensed Shigella vaccine currently exists. The SUNSHINE trial is assessing the safety and immunogenicity of the InvaplexAR-Detox/dmLT vaccine candidate. The trial began in the Netherlands in October 2024 and, once safety was confirmed, continued in Zambia, a Shigella-endemic setting. The final trial results are expected soon.

Prioritise:

  • PrIMAVeRa is building an open-access decision-support platform that integrates clinical, epidemiological and health economic data to help prioritise vaccines and monoclonal antibodies against AMR. It gives policymakers and funders the evidence to invest where the impact on AMR will be greatest.


Diagnose:

  • DRAIGON is developing a diagnostic device that combines whole-genome sequencing with artificial intelligence. It aims to give rapid, accurate detection of multi-drug-resistant infections, focusing on bloodstream and prosthetic joint infections. Faster answers mean the right treatment sooner, and better surveillance of resistance.

 

Prevention, prioritisation and rapid diagnosis are different parts of the same response. In line with this year’s theme, EVI works with researchers, industry, clinicians and policymakers across sectors and borders to keep life-saving approaches effective.

 

_______





ShigaPlexIM is part of the EDCTP2 Programme supported by the European Union (RIA2018V-2308) 




DRAIGON: Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.​ 





PrIMAVeRA has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use made of the information contained therein.

 

 
 
bottom of page